Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Telomir-1
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir-1 Shows Potential As First-In-Class Epigenetic Therapy
Details : Telomir-1 was shown to potently inhibit UTX (KDM6A), an enzyme that acts like an "eraser" of chemical tags on DNA packaging proteins. Currently being investigated for the treatment of cancer.
Product Name : Telomir-1
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir-1 Restores Vision and Retinal Health in AMD Using FDA Surrogate Endpoints
Details : Telomir-1 to fully reverse copper-induced elevation of Reactive Oxygen Species (ROS) and provide robust cellular protection against copper toxicity.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 29, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : The Bayshore Trust
Deal Size : $3.0 million
Deal Type : Financing
Telomir Raises $3M Straight Equity to Advance Rare Disease IND With No Warrants
Details : The financing aims to advance the clinical development of theTelomir-1, which is being evaluated for the treatment of type 2 diabetes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 21, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : The Bayshore Trust
Deal Size : $3.0 million
Deal Type : Financing
Lead Product(s) : Telomir-1
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir Shows Strong Anti-Cancer Effects in Prostate Cancer Model
Details : Telomir-1 is the first novel small molecule, which suppresses cancer growth rather than promoting it and protects against chemotherapy-induced toxicity and mortality.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir-1 Reverses Calcium Dysregulation, Key Aging Driver, in Human Cell Study
Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 26, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir Pharmaceuticals Reduces Oxidative Stress, Advancing AMD Treatment
Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir-1 Reverses Oxidative Stress, Explored for Avian Flu, Other Viruses
Details : Telomir-1 to fully reverse copper-induced elevation of reactive oxygen species (ROS) and provide robust cellular protection against copper toxicity in viral infections, such as avian influenza.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir Pharmaceuticals Confirms Lifespan Restoration in Progeria Model
Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions, like progeria.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Telomir-1
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Telomir Pharmaceuticals Confirms Copper Binding Of Telomir-1 for Wilson's Disease
Details : Telomir-1 is the first novel small molecule, which is proposed to be dosed orally, to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 23, 2024
Lead Product(s) : Telomir-1
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Telomir-1
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : Starwood Trust
Deal Size : $1.0 million
Deal Type : Financing
Telomir Pharmaceuticals Raises $1M with No-Warrant Stock Deal at 20% Premium
Details : The financing aims to advance the company's lead product Telomir-1. It is being evaluated for the treatment of osteoarthritis and Aging.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 12, 2024
Lead Product(s) : Telomir-1
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : Starwood Trust
Deal Size : $1.0 million
Deal Type : Financing